Table 1.

A list of the 12 patients receiving riluzole on the trial

Patient no.ToxicityPre- and post-tumorB-Raf or N-RasClinical or radiologic responseSuppression of MAPKSuppression of PI3K/AKT
1NonePre onlyWT??NANA
2Dry mouthYesV600EYesYesYes
3NoneYesWTNoNoNo
4Dry mouthYesWTNoNoNo
5DizzinessYesQ61KYesYesYes
6NoneYesWTNoNoNo
7NoneYesWTYesNoNo
8NoneYesWTYesNoNo
9NoneYesWTYesYesYes
10DizzinessPre onlyWTNANANA
11DizzinessYesV600KYesYesNo
12NoneYesWTNoNoNo
  • NOTE: Patient no. 1 had no viable tumor on final resection and patient no. 10 was removed from study for grade 3 toxicity (dizziness); thus, only 10 pairs of tumor specimens were available for study. Patients 2, 5, 9, and 11 had clinical or radiologic evidence of response to riluzole administration as well as metabolic evidence of suppression of the MAPK (all four) and PI3K/AKT (all but patient 11) pathways. Patients 7 and 8 had clinical or radiologic evidence of response to riluzole administration but no suppression of the MAPK or PI3K/AKT pathways. Patient 10 was the only patient to be removed from study for toxicity.

  • Abbreviation: NA, not applicable.